New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsComparePT-141 (Bremelanotide) vs Testagen

PT-141 (Bremelanotide) vs Testagen

Side-by-side comparison of key properties, dosing, and research.

Sexual Health & Libido
PT-141 (Bremelanotide)
Anti-Aging & Longevity
Testagen
Summary
PT-141 (Bremelanotide) is a cyclic peptide melanocortin receptor agonist that enhances sexual desire and arousal through central nervous system mechanisms. It is FDA-approved as Vyleesi for premenopausal women with hypoactive sexual desire disorder (HSDD).
Testagen is a tetrapeptide bioregulator (Lys-Glu-Asp-Gly) developed by Professor Vladimir Khavinson, tissue-specific for the testes. It supports Leydig cell function, normalization of testosterone biosynthesis, and spermatogenic activity. Testagen is used in men's health protocols for age-related testosterone decline, male fertility support, and testicular anti-aging.
Half-Life
2–3 hours
Short (minutes); sustained gene-regulatory effects
Admin Route
SubQ
SubQ, Oral
Research
Typical Dose
0.5–1.75 mg
10 mg per day
Frequency
As needed (not daily)
Daily for 10–30 days
Key Benefits
  • Enhances sexual desire and libido in both men and women
  • Improves arousal through central nervous system activation
  • Effective for psychological erectile dysfunction
  • Works for female sexual arousal disorder
  • May improve sexual satisfaction and intensity
  • Fast-acting — effects within 45–60 minutes
  • FDA-approved for HSDD in premenopausal women
  • Supports endogenous testosterone synthesis via Leydig cell normalization
  • Promotes spermatogenesis and sperm quality
  • Anti-aging effects on testicular tissue
  • May attenuate age-related testosterone decline
  • Mechanistically distinct from TRT — does not suppress HPG axis
  • Useful adjunct to Gonadorelin and Kisspeptin-10 in male hormonal protocols
  • Supports male fertility without exogenous hormone replacement
Side Effects
  • Nausea (most common — 40% of users in clinical trials)
  • Facial flushing and warmth
  • Transient blood pressure changes (typically increase then normalize)
  • Headache
  • +2 more
  • Generally well tolerated
  • Mild injection site reactions
  • No significant endocrine disruption reported at standard doses
Stacks With